Trametinib (Mekinist) is a MEK 1 and MEK 2 inhibitor. It stops the growth and spread of the tumor cells in patients with melanoma, lung, and thyroid cancers.
Indications of Trametinib (Mekinist):
-
Melanoma:
- It is used in combination with dabrafenib in patients with BRAF V600E or BRAF V600K mutations, lymph node involvement, following complete resection OR
- The treatment of unresectable or metastatic melanoma in patients as a single agent or combination therapy.
-
Metastatic Non-small cell lung cancer:
- It is indicated as combination therapy for the treatment of metastatic non-small cell lung cancer in patients with BRAF V600E mutation.
-
Locally advanced or metastatic anaplastic thyroid cancer:
- It is used in combination for treating locally advanced or metastatic anaplastic thyroid malignancy with BRAF V600E mutation and with no satisfactory locoregional treatment options.
Trametinib (Mekinist) dose Adults
Note: BRAF V600 mutation status should be verified before treatment.
Trametinib (Mekinist) dose for the treatment Melanoma as adjuvant therapy (with BRAF V600E or BRAF V600K mutations):
- 2 mg per oral once daily (in combination with dabrafenib);
- continue for ≤1 year in the absence of disease progression or unacceptable toxicity.
Trametinib (Mekinist) dose for the treatment of metastatic or unresectable Melanoma (with BRAF V600E or BRAF V600K mutations):
- 2 mg per oral once daily (monotherapy or in combination with dabrafenib),
- continue until disease progression or unacceptable toxicity.
Trametinib (Mekinist) dose for the treatment of metastatic Non-small cell lung cancer (with BRAF V600E mutation):
- 2 mg per oral once daily (in combination with dabrafenib);
- continue until disease progression or unacceptable toxicity.
Trametinib (Mekinist) dose for the treatment of locally advanced or metastatic Anaplastic Thyroid cancer (with BRAF V600E mutation):
- 2 mg per oral once daily (in combination with dabrafenib); continue until disease progression or unacceptable toxicity.
Missed doses:
- Do not take a missed dose within 12 hours of the next dose.
FDA prescribing information is available in PDF.
Use in Children:
The safety and efficacy of the drug in children have not been established.
Pregnancy Risk Category D
- Studies on animal reproduction showed that fetal harm was evident.
- Effective contraceptives should be used by both males and females with reproductive potential during trametinib treatment and for at least 4 months following the last trametinib dosage.
Use while breastfeeding
- It is not known if Trametinib is excreted in breast milk.
- Due to serious side effects, the manufacturer does not recommend breastfeeding during trametinib therapy or for at least 4 months after the last dose.
Trametinib (Mekinist) Dose adjustment in renal disease:
-
Mild to moderate impairment (GFR ≥30 mL/minute/1.73 m²):
- No dosage adjustment necessary.
-
Severe impairment (GFR <30 mL/minute/1.73 m²):
- There are no dosage adjustments provided in the manufacturer's labeling.
Trametinib (Mekinist) Dose adjustment in liver disease:
-
Mild impairment bilirubin ≤ upper normal limit and AST > upper normal limit or bilirubin >1 to 1.5 times upper normal limit with any AST:
- No dosage adjustment necessary.
-
Moderate bilirubin >1.5 to 3 times upper normal limit and any AST to severe bilirubin >3 to 10 times upper normal limit and any AST impairment:
- There are no dosage adjustments provided in the manufacturer's labeling (an appropriate dose has not been established).
Common Side Effects of Trametinib (Mekinist) monotherapy:
-
Cardiovascular:
- Hypertension
- Cardiomyopathy
-
Dermatologic:
- Skin Toxicity
- Skin Rash
- Acneiform Eruption
- Xeroderma
-
Endocrine & Metabolic:
- Hypoalbuminemia
-
Gastrointestinal:
- Diarrhea
- Stomatitis
- Abdominal Pain
-
Hematologic & Oncologic:
- Anemia
- Lymphedema
- Hemorrhage
-
Hepatic:
- Increased Serum Aspartate Aminotransferase
- Increased Serum Alanine Aminotransferase
- Increased Serum Alkaline Phosphatase
Rare Side Effects of Trametinib (Mekinist):
-
Cardiovascular:
- Decreased Left Ventricular Ejection Fraction
- Bradycardia
-
Central Nervous System:
- Dizziness
-
Dermatologic:
- Paronychia
- Pruritus
- Cellulitis
- Folliculitis
- Pustular Rash
-
Gastrointestinal:
- Dysgeusia
- Xerostomia
-
Neuromuscular & Skeletal:
- Rhabdomyolysis
-
Ophthalmic:
- Blurred Vision
- Dry Eye Syndrome
-
Respiratory:
- Interstitial Pulmonary Disease
- Pneumonitis
Side effects reported with dual therapy (trametinib plus dabrafenib):
Common Side Effects of Trametinib (Mekinist):
-
Cardiovascular:
- Hypertension
- Peripheral Edema
- Prolonged Q-T Interval On ECG
-
Central Nervous System:
- Fatigue
- Headache
- Chills
- Dizziness
-
Dermatologic:
- Skin Toxicity
- Skin Rash
- Xeroderma
-
Endocrine & Metabolic:
- Hyperglycemia
- Hyponatremia
- Hypoalbuminemia
- Hypophosphatemia
- Exacerbation Of Diabetes Mellitus
-
Gastrointestinal:
- Nausea
- Vomiting
- Diarrhea
- Decreased Appetite
- Abdominal Pain
- Constipation
-
Hematologic & Oncologic:
- Neutropenia
- Leukopenia
- Anemia
- Lymphocytopenia
- Hemorrhage
- Thrombocytopenia
- Malignant Neoplasm
-
Hepatic:
- Increased Serum Alkaline Phosphatase
- Increased Serum Aspartate Aminotransferase
- Increased Serum Alanine Aminotransferase
-
Neuromuscular & Skeletal:
- Arthralgia
- Myalgia
-
Renal:
- Increased Serum Creatinine
-
Respiratory:
- Cough
- Dyspnea
-
Miscellaneous:
- Fever
- Febrile Reaction
Rare Side Effects of Trametinib (Mekinist) (dual therapy):
-
Cardiovascular:
- Bradycardia
- Cardiomyopathy
- Reduced Ejection Fraction
- Venous Thromboembolism
- Hypertension
-
Central Nervous System:
- Intracranial Hemorrhage
-
Gastrointestinal:
- Gastrointestinal Hemorrhage
- Pancreatitis
-
Hematologic & Oncologic:
- Basal Cell Carcinoma
- Squamous Cell Carcinoma Of Skin
-
Neuromuscular & Skeletal:
- Rhabdomyolysis
-
Ophthalmic:
- Blurred Vision
-
Respiratory:
- Pneumonitis
Contraindication to Trametinib (Mekinist):
The US labeling of the manufacturer does not list any contraindications. Canadian labeling: Hypersensitivity of trametinib and any component of the formulation.
Warnings and precautions
-
Suppression of bone marrow
- When taken concurrently with dabrafenib, it can cause neutropenia.
-
Cardiac events
- This can lead to heart failure, or decreased left ventricular ejection percentage. Therefore, an echocardiogram and MUGA scan are required at regular intervals.
- In severe cases, it may be necessary to reduce or stop the dose.
-
Dermatologic toxicities:
- In severe cases, drug therapy should be stopped.
-
Febrile reactions
- Combining trametinib with dabrafenib can cause fever, hypotension, rigors/chills or renal failure.
- If the fever persists for more than 3 days or complications occur, corticosteroids are recommended.
-
Events in the gastrointestinal tract:
- It can lead to life-threatening colitis or GI perforation.
-
Hemorrhage
- Drug therapy can lead to fatal intracranial, retroperitoneal, and gastrointestinal hemorhages.
-
Hepatotoxicity
- Trametinib has been linked to liver dysfunction.
-
Hyperglycemia
- Combination therapy with trametinib/dabrafenib may cause hyperglycemia. Therefore, glucose monitoring or insulin therapy may be necessary.
-
Hypertension
- You should use it with caution as hypertension can result.
-
Malignancy
- Basal cell carcinoma and cutaneous squamous cells carcinoma can both be detected in single-agent therapy or dual therapy.
- Dermatological exams should be done before treatment begins, every 2 months, during treatment, and up to 6 months after discontinuation.
-
Ocular toxicities:
- There are two possible outcomes: retinal vein occlusion and retinal pigment epithelial dissociation (RPED).
- These can lead to macular edema, reduced visual function, neovascularization and glaucoma.
- If a retinal vein occlusion occurs, the drug should immediately be stopped
- If iritis or uveitis occurs, it should be treated immediately with mydriatic drops and ophthalmic steroids.
-
Toxicity in the lungs:
- Pneumonitis and interstitial lung disease can present with symptoms such as cough, dyspnea or hypoxia.
-
Venous thromboembolism
- You should be aware that it can lead to pulmonary embolism and fatal deep vein thrombosis.
Trametinib: Drug Interaction
Dabrafenib |
Trametinib may enhance the adverse/toxic effect of Dabrafenib. |
Monitoring parameters:
- Blood glucose
- LFTs
- Echo and MUGA scan to assess LVF status
- BRAF V600K or V600E mutation status before treatment
- Pregnancy
- Ophthalmic exam
- Signs/symptoms of pulmonary/dermatological toxicity.
- Signs/symptoms of infection
- Signs/symptoms of cutaneous and noncutaneous malignancies
How to administer Trametinib (Mekinist):
- It should be taken orally at least one hour before or two hours after a meal.
- Dosage should be taken at the same time every day.
- Trametinib should not be given more than once a day.
Mechanism of action of Trametinib (Mekinist):
- Trametinib selectively inhibits mitogen-activated ex kinase 1 and 2 activation, kinase activity, leading to decreased cell proliferation, cell cycle arrest and increased apoptosis.
- Combining trametinib with dabrafenib causes MAPK pathway inhibition at a greater scale.
- This results in BRAF V600 melanoma cells dying. Combining dabrafenib with Trametinib results in synergistic inhibitions of cell growth in lung carcinoma cell lines that are BRAF V600E mutation.
Absorption:
- Rapid; decreased with a high-fat, high-calorie meal (1,000 calories)
Distribution:
- 214 L
Protein binding:
- 97% to plasma proteins
Metabolism:
- Predominantly deacetylation (via hydrolytic enzymes) alone or with monooxygenation or in combination with glucuronidation
Bioavailability:
- 72%
Half-life elimination:
- 4 to 5 days
Time to peak:
- 1.5 hours; delayed with a high-fat, high-calorie meal (1,000 calories)
Excretion:
- Feces (>80%)
- urine (<20% with <0.1% as unchanged drug)
International Brands of Trametinib:
- Mekinist
Trametinib Brand Names in Pakistan:
No Brands Available in Pakistan.